Preparation and chemical and spectroscopic properties of (disilylamino)difluorophosphine and bis(difluorophosphino)silylamine
作者:E. A. V. Ebsworth、David W. H. Rankin、John G. Wright
DOI:10.1039/dt9790001065
日期:——
N(PF2)2(SiH3) have been prepared by the reactions of SiBrH3 and NMe3 with PF2[NH(SiH3)] and NH(PF2)2 respectively. Vibrational, n.m.r., mass, and photoelectron spectra have been recorded, and chemicalproperties have been studied. With diborane, PF2[N(SiH3)2] gives the adduct PF2[N(SiH3)2]·BH3 and N(PF2)2(SiH3) gives both mono- and bis-(borane) adducts; n.m.r. spectre of the three borane adducts have
Apparatus and method for the condensed phase production of trisilylamine
申请人:L'Air Liquide Société Anonyme pour l'Etude et L'Exploitation des Procédés Georges Claude
公开号:US09446958B2
公开(公告)日:2016-09-20
The present invention is directed to a condensed phase batch process for synthesis of trisilylamine (TSA). An improved synthesis process that incorporates a solvent to help promote a condensed-phase reaction between ammonia gas (or liquid) and liquified monochlorosilane (MCS) in good yields is described. This process facilitates the removal of the byproduct waste with little to no reactor down time, substantial reduction of down-stream solids contamination and high-purity product from first-pass distillation.
Apparatus and method for the production of trisilyamine
申请人:Voltaix, Inc.
公开号:US08669387B2
公开(公告)日:2014-03-11
There is described a process for preparing silylamines in and particularly trisilylamine (TSA) in high yields in a tubular laminar flow, plug flow reactor, from ammonia gas and a monohalosilane gas. The apparatus can be a tubular flow reactor comprising a first portion of the reactor defining a gas entry zone, a second portion of the reactor defining a reaction zone and a third portion of the reactor defining a separation zone, the reaction zone providing a reactant contacting region. Trisilylamine can be recovered in the separation zone in a cold trap collection vessel.
Human RNase H1 and oligonucleotide compositions thereof
申请人:ISIS Pharmaceuticals, Inc.
公开号:US20040102618A1
公开(公告)日:2004-05-27
The present invention provides oligonucleotides that can serve as substrates for human Type 2 RNase H. The present invention is also directed to methods of using these oligonucleotides in enhancing antisense oligonucleotide therapies.
Oligonucleotides having A-DNA form and B-DNA form conformational geometry
申请人:——
公开号:US20030096979A1
公开(公告)日:2003-05-22
Modified oligonucleotides containing both A-form conformation geometry and B-from conformation geometry nucleotides are disclosed. The B-form geometry allows the oligonucleotide to serve as substrates for RNase H when bound to a target nucleic acid strand. The A-form geometry imparts properties to the oligonucleotide that modulate binding affinity and nuclease resistance. By utilizing C2′ endo sugars or O4′ endo sugars, the B-form characteristics are imparted to a portion of the oligonucleotide. The A-form characteristics are imparted via use of either 2′-O-modified nucleotides that have 3′ endo geometries or use of end caps having particular nuclease stability or by use of both of these in conjunction with each other.